StockNews.com assumed coverage on shares of Aethlon Medical (NASDAQ:AEMD – Free Report) in a research report report published on Monday. The firm issued a sell rating on the medical equipment provider’s stock.
Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Aethlon Medical in a research report on Friday, November 15th.
Aethlon Medical Stock Performance
Aethlon Medical Company Profile
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
See Also
- Five stocks we like better than Aethlon Medical
- Options Trading – Understanding Strike Price
- How to Master Trading Discipline: Overcome Emotional Challenges
- Trading Stocks: RSI and Why it’s Useful
- Trump Tax Reforms: 7 Stocks That Could Benefit in 2025
- How to Calculate Options Profits
- 3 Stocks Near 52-Week Lows: Why They Could Be Smart Buys Today
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.